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Introduction
A hallmark of atherogenesis is focalized endothelial dysfunc-
tion, which includes altered vasoregulation, activation of in-
flammatory processes, and compromised barrier function caused 
by endothelial cell (EC) apoptosis (Hu et al., 1999; Song et al., 
2008).  Manifestations  of  dysfunctional  ECs  are  readily  ob-
served in certain areas of the arterial tree, where disturbed flow 
(d-flow), hence reduced time-averaged shear stress, develops 
(Traub and Berk, 1998; Won et al., 2007). Steady laminar flow 
(s-flow) promotes release of factors from ECs that inhibit coagu-
lation, leukocyte diapedesis, and smooth muscle cell prolifera-
tion while simultaneously promoting EC survival (Garin et al., 
2007; Reinhart-King et al., 2008). Conversely, d-flow alters the 
profile of secreted factors and EC surface molecule expression 
that favors the opposite effects, thereby contributing to the de-
velopment of atherosclerosis (Traub and Berk, 1998). We have 
previously reported the critical role of PKC activation in EC 
apoptosis  (Garin  et  al.,  2007).  Importantly,  s-flow  interferes 
with PKC signaling, thereby down-regulating the proapoptotic 
effect of the kinase. In contrast, unique atheroprone signals elic-
ited by d-flow remain unclear.
Acting as a sensor for DNA damage, the transcription fac-
tor p53 is a key regulator of the life or death of a cell, depending 
on whether or not the cell can cope with the damage and repair 
it. Although the most-studied function of p53 is its role as a 
transcription factor that increases the expression of proapop-
totic genes (Murray-Zmijewski et al., 2008), recent studies have 
revealed its nontranscriptional proapoptotic activities. Cytosolic 
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therosclerosis is readily observed in regions of 
blood vessels where disturbed blood flow (d-flow) 
is known to occur. A positive correlation between 
protein kinase C  (PKC) activation and d-flow has been 
reported,  but  the  exact  role  of  d-flow–mediated  PKC 
  activation in atherosclerosis remains unclear. We tested 
the  hypothesis  that  PKC  activation  by  d-flow  induces 
  endothelial  cell  (EC)  apoptosis  by  regulating  p53.  We 
found that d-flow–mediated peroxynitrite (ONOO
) in-
creased PKC activation, which subsequently induced 
p53 SUMOylation, p53–Bcl-2 binding, and EC apoptosis. 
Both d-flow and ONOO
 increased the association of 
PKC with protein inhibitor of activated STATy (PIASy) 
via the Siz/PIAS-RING domain (amino acids 301–410) 
of  PIASy,  and  overexpression  of  this  domain  of  PIASy 
  disrupted the PKC–PIASy interaction and PKC-mediated 
p53 SUMOylation. En face confocal microscopy revealed 
increases  in  nonnuclear  p53  expression,  nitrotyrosine 
staining,  and  apoptosis  in  aortic  EC  located  in  d-flow 
  areas in wild-type mice, but these effects were significantly 
decreased in p53
/ mice. We propose a novel mecha-
nism for p53 SUMOylation mediated by the PKC–PIASy 
interaction during d-flow–mediated EC apoptosis, which 
has potential relevance to early events of atherosclerosis.
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Reactive oxygen species has been shown to react with NO 
and generate ONOO
, reducing NO availability and accelerat-
ing endothelial dysfunction and development of atherosclerosis 
(Ponnuswamy et al., 2009). Furthermore, it has been reported 
that ONOO
 was increased by d-flow both in vitro and in vivo 
(Hsiai et al., 2007). To test whether some effects of d-flow 
could be mediated by ONOO
, we treated ECs with ONOO
 
and examined PKC activation. Indeed, ONOO
 also increased 
PKC phosphorylation at both Thr410 and Thr560 within 5 min 
of stimulation, reaching its maximum by 10 min (Fig. 1 D), sug-
gesting that ONOO
-mediated PKC kinase activation is similar 
to d-flow stimulation.
PKC activation by d-flow and ONOO
 
induces apoptosis
We examined whether PKC activation was also required for 
d-flow and ONOO
-mediated EC apoptosis using two different 
approaches. PKC activity was down-regulated by inhibiting 
its expression by siRNA and also by expressing an adeno-
viral  dominant-negative  (DN)  kinase-dead  form  of  PKC 
(Ad-DN-PKC). Although d-flow and ONOO
 treatment in-
creased apoptosis in control cells, a significant reduction in the 
number of TUNEL-positive cells was noted in PKC-depleted 
HUVECs (Fig. 2, A and B, left). When HUVECs were infected 
with Ad-DN-PKC (mutating Lys281to Met), the ONOO
-
induced increase in TUNEL-positive cells and the expression of 
cleaved caspase 3 fragments (17/19 kD) were reduced com-
pared with control cells (Fig. 2, B [center] and C). These data 
suggest the critical role of PKC kinase activity in d-flow and 
ONOO
-mediated EC apoptosis.
ONOO
 induces p53 nuclear  
export and binding to Bcl-2 in a  
PKC-dependent manner
p53  promotes  transcription  of  several  proapoptotic  genes 
(Mihara et al., 2003; Mercer et al., 2005; Bischof et al., 2006; 
Garner et al., 2007). To test whether it plays a role in the 
ONOO
-induced EC apoptosis, we first examined the effect of 
ONOO
 on p53 transcriptional activity in HUVECs that were 
overexpressing p53 with or without coexpression of a constitu-
tively active PKC (catalytic domain of PKC [CAT]; Garin 
et al., 2007). To our surprise, ONOO
 inhibited p53 transcrip-
tional activity in control cells and also in those overexpressing 
p53 (Fig. 3 A). Consistent with these results, cells transfected 
with CAT also showed a decreased p53 transcriptional activity 
(Fig. 3 B). These results strongly suggest that ONOO
-mediated 
EC apoptosis is not caused by increased p53 transcriptional acti-
vation of proapoptotic genes.
It has recently been reported that cytosolic p53 directly 
interacts with Bcl-2 and antagonizes its antiapoptotic stabiliza-
tion of the outer mitochondrial membrane (Mihara et al., 2003; 
Bischof et al., 2006). Because this interaction takes place in the 
cytoplasm, p53 may be exported from the nucleus when PKC 
is activated by ONOO
. To verify this possibility, HUVECs 
were stimulated with ONOO
 for 4 h, and p53 localization was 
analyzed by immunostaining (Fig. 3 C). Interestingly, the anti-
p53 staining contrast between the nucleus and the cytoplasm in 
p53  directly  interacts  with  the  B  cell  lymphoma/leukemia-2 
(Bcl-2) family member proteins Bcl-xL and Bcl-2 and an-
tagonizes their antiapoptotic function by stabilizing the outer 
mitochondrial membrane (Mihara et al., 2003). Interestingly, 
antiapoptotic effects of p53 have also been reported (Mercer et al., 
2005; Garner and Raj, 2008). It is particularly interesting that p53 
inhibits apoptosis of vascular smooth muscle cells and protects 
against atherosclerosis formation (van Vlijmen et al., 2001; Mercer 
et al., 2005). However, it remains unclear how these p53 functions, 
especially its apoptotic effect in ECs, are regulated by flow.
SUMOylation is a posttranslational modification consist-
ing of covalent conjugation of ubiquitin-like proteins called 
SUMO (small ubiquitin-like modifier) to target proteins (Hilgarth 
et al., 2004). It is a reversible modification that affects target 
protein functions, such as subcellular localization, protein part-
nering, DNA binding, and regulation of transcription factors 
(Hilgarth et al., 2004). Carter et al. (2007) proposed an interest-
ing model for p53 nuclear export and stabilization. Masking of 
the C-terminal nuclear export signal (NES) results in nuclear 
localization of unmodified p53. A low level of ubiquitination 
by MDM2 exposes the NES, promoting p53 to interact with 
protein inhibitor of activated STATy (PIASy) and further modi-
fication by SUMOylation causes p53 nuclear export (Carter et al., 
2007). These data suggest an important role of SUMOylation 
in p53 nuclear export. In this study, we investigate the role of 
PKC and PIASy on d-flow–mediated endothelial p53 nuclear 
export and apoptosis, which may contribute to EC dysfunction 
and subsequent atherosclerotic plaque formation. Furthermore, 
we show that the cytoplasmic expression of p53 and EC apop-
tosis are increased in ECs in the area of d-flow in vivo.
Results
D-flow and ONOO
, but not s-flow,  
activate PKC
We first verified the potential role of shear stress in PKC acti-
vation in cultured ECs using a cone and plate type of flow appa-
ratuses as described previously (Reinhart-King et al., 2008). To 
generate d-flow, we used cones with radial grooves that were 
1-mm deep. Fig. 1 (A and B) shows tracks of fluorescent beads 
suspended  in  culture  media  when  grooved  and  nongrooved 
cones were rotated at the same speed. Although the nongrooved 
cone  created  straight  unidirectional  tracks  indicating  s-flow, 
tracks made by the grooved cone were short and not oriented 
in the same direction, indicating nonlaminar movement of the 
media in the dish. Using these cones, we determined the effect 
of s- and d-flow on PKC activation in human umbilical vein 
ECs (HUVECs). D-flow increased PKC phosphorylation at 
both Thr410 and Thr560 after 10 min of stimulation (Fig. 1 C), 
whereas s-flow failed to activate PKC, although ERK5 was 
  activated by s-flow as we reported previously (not depicted; 
Woo et al., 2008). PKC phosphorylation at Thr560 was sus-
tained longer than phosphorylation at Thr410. These data ob-
tained from our in vitro system are consistent with in vivo data, 
which showed increased PKC activity in d-flow area compared 
with s-flow area in porcine arteries (Magid and Davies, 2005), 
supporting the physiological relevance of our in vitro system.869 D-flow–induced PKC activation and p53 SUMOylation • Heo et al.
Next, to examine whether PKC is involved in ONOO
-
mediated p53–Bcl-2 association, we expressed Ad-DN-PKC 
in HUVECs, treated them with ONOO
, and performed a co-
immunoprecipitation assay using anti-p53 followed by immuno-
blotting with anti–Bcl-2. Bcl-2 coimmunoprecipitated with p53 
when control cells (transduced with Ad-LacZ) were treated with 
ONOO
 for 10 min or longer, but this coimmunoprecipitation was 
strongly inhibited by Ad-DN-PKC expression (Fig. 3 D and 
ONOO
-treated cells decreased considerably, and some punc-
tuate staining appeared in the cytoplasm (Fig. 3 C). No fluores-
cent signal was detected when only the secondary antibodies 
were used (unpublished data). ONOO
-induced anti-p53 stain-
ing in the cytoplasm was reduced in Ad-DN-PKC–transduced 
cells compared with adenovirus of LacZ (Ad-LacZ)–transduced 
cells, suggesting that ONOO
 induced p53 export from the nu-
cleus in a PKC-dependent manner.
Figure  1.  PKC  activation  by  d-flow  and  ONOO
.  
(A and B) Generation of s-flow and d-flow using a cone and 
plate flow chamber. Tracks of fluorescent beads in a cone 
and plate flow chamber. S-flow was generated using a 
nongrooved cone (A), and d-flow was generated using 
a grooved cone (B). Note straight tracks with s-flow and 
short tracks with different orientations with d-flow, which 
are caused by beads going out of focus. Both cones were 
rotated at the same speed. Color tracks indicate time x 
(red), time x + 10 s (green), and time x + 20 s (blue). 
Bright dots are beads adhered to the dish. Exposure time 
is 0.4 s. Bars, 100 µm. (C and D) HUVECs were stimu-
lated by s- or d-flow (C) or ONOO
 (D) for the indicated 
times,  and  PKC  phosphorylation  was  determined  by 
Western blotting. The level of PKC phosphorylation was 
determined by taking the ratio of optical densities between 
antiphospho-PKC and anti-PKC bands (bar graphs) as 
described  in  Materials  and  methods.  The  experiments 
were performed in triplicate using three different batches 
of s- or d-flow or ONOO
-stimulated HUVECs (means ± 
SD; n = 3; *, P < 0.05; and **, P < 0.01 compared 
with control). Molecular masses are given in kilodaltons. 
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may be controlled by PKC. To test this, we cotransfected HeLa 
cells  with  Flag-tagged  p53  (Flag-p53),  HA-tagged  SUMO3 
(HA-SUMO), and constitutively active PKC (CAT) and de-
termined  p53  SUMOylation  by Western  blotting  using  anti-
SUMO2/3. Several bands presumably representing mono- and 
poly-SUMOylated p53 with apparent molecular masses of 68, 
74, 82, 130, 185, and 200 kD were noted (Fig. 4 A). These 
bands were also labeled by anti-Flag, indicating that they are 
SUMOylated Flag-p53 (Fig. 4 A, middle). p53 SUMOylation 
was increased in CAT-transfected cells, suggesting the role of 
Fig. S1, A and C). Nonimmune control IgG failed to bring down 
p53 and Bcl-2 (Fig. S1 A). Collectively, these results suggest a 
role of PKC in ONOO
-mediated p53 nuclear export and sub-
sequent p53–Bcl-2 interaction.
PKC mediates d-flow– and ONOO
-induced 
p53 SUMOylation
Because  p53  nuclear  export  is  positively  regulated  by   
SUMOylation (Bischof et al., 2006) and also because PKC 
regulates p53 nuclear export (present study), p53 SUMOylation 
Figure 2.  PKC depletion by siRNA and DN-PKC inhibits d-flow and ONOO
-induced apoptosis. (A) HUVECs were transfected with control or PKC 
siRNA for 48 h and then stimulated with d-flow for 36 h followed by TUNEL staining. Images were recorded as described in Materials and methods after 
counterstaining with DAPI to visualize nuclei (bottom). Apoptotic nuclei appear green (top). Bars, 25 µm. (right) Quantification of apoptosis is shown as 
the percentage of TUNEL-positive cells. (B) HUVECs were transfected with control or PKC siRNA for 48 h (left) or transduced with Ad-DN-PKC or Ad-LacZ 
as a control for 24 h (center). Cells were then treated with 100 µM ONOO
 or vehicle for 8 h and assayed by TUNEL staining. (right) DN-PKC and 
reduced PKC expression were confirmed by Western blotting with anti-PKC. Data are from three separate experiments using two or more different EC 
preparations (**, P < 0.01). (C) After transduction of Ad-DN-PKC or Ad-LacZ for 24 h, HUVECs were treated with 100 µM ONOO
 for 9 and 18 h, and 
Western blotting with anti–cleaved caspase 3 was performed. DN-PKC expression and protein loading were assessed by Western blotting with anti-PKC 
(middle) and antitubulin (bottom). (right) Quantification of cleaved caspase 3 is expressed as the relative ratio compared with tubulin expression. Results 
are expressed as the relative percentage of untreated cells in the LacZ control (100%). n = 3. **, P < 0.01 compared with each control. Molecular masses 
are given in kilodaltons. Error bars are means ± SD.871 D-flow–induced PKC activation and p53 SUMOylation • Heo et al.
Coimmunoprecipitation  using  nonimmune  IgG  yielded  no 
SUMOylated bands (Fig. S1 A). To see whether endogenous 
p53 is SUMOylated, we specifically inhibited p53 expression 
using  siRNA  and  found  significantly  reduced  SUMOylation 
levels in the 68-, 74-, 82-, 130-, 160-, and 185-kD bands (Fig. 4 C). 
Endogenous p53 SUMOylation bands were less discrete, likely 
caused  by  the  combined  effects  of  poly-SUMOylation  and 
ubiquitination  as  previously  described  (Carter  et  al.,  2007). 
SENP2  (sentrin-specific  protease  2)  is  a  de-SUMOylation 
enzyme that is important for both processing new SUMO 
PKC activity on p53 SUMOylation. In addition, these su-
moylated bands were diminished in the cells transfected with the 
p53-K386R SUMOylation mutant (Kwek et al., 2001), further 
supporting that these high mass bands were SUMOylated p53.
An important role of PIASy as a SUMO E3 ligase in p53 
SUMOylation has been reported (Bischof et al., 2006). To con-
firm that the 4–5 bands are SUMOylated p53, HUVECs with or 
without CAT expression were transfected with PIASy siRNA. 
This should inhibit p53 SUMOylation, and indeed, PIASy de-
pletion eliminated the appearance of these bands (Fig. 4 B). 
Figure  3.  PKC  mediates  ONOO
-induced  p53  nuclear  export  and  p53–Bcl-2  binding  instead  of  the  regulation  of  p53  transcriptional  activity.   
(A and B) HUVECs were transfected with the p53-Luc reporter and Renilla luciferase–encoding plasmid (pRL- thymidine kinase) used as an internal control 
reporter together with p53–wild type or vector alone (pcDNA3.1; A). Some cells were further transfected with or without pcDNA3.1-CAT (B). Transcrip-
tional activity was determined by a reporter plasmid encoding 13 copies of the p53-binding sequence (p53-Luc reporter; Kern et al., 1992). After 24 h of 
transfection, p53 transcriptional activity was assayed using the dual-luciferase kit (B), or the cells were further treated with 10 or 50 µM ONOO
 for 8 h 
as indicated, and luciferase activity was assayed (A). Data are representative of triplicates using two or more different preparations of ECs. *, P < 0.05; 
**, P < 0.01. (C) HUVECs were transduced with Ad-DN-PKC or Ad-LacZ as a control for 24 h, treated with vehicle or 100 µM ONOO
 for 4 h, and   
immunostained with anti-p53 followed by DAPI counter staining for nuclei. Bar, 5 µm. (D, top) HUVECs were transduced with Ad-DN-PKC or Ad-LacZ for   
24 h and stimulated with 100 µM ONOO
– for the indicated times. p53–Bcl-2 binding was determined by coimmunoprecipitation with anti-p53 followed by 
immunoblotting with anti–Bcl-2. p53, PKC, and Bcl-2 in total cell lysates were detected by Western blotting with each specific antibody. (bottom) Quantifi-
cation of p53–Bcl-2 binding expressed as the relative band intensity ratio between coimmunoprecipitated versus total Bcl-2. Results were normalized as described 
in Fig. 1. n = 3. *, P < 0.05 and **, P < 0.01 compared with the vehicle control, and 
#, P < 0.05 and 
##, P < 0.01 compared with the LacZ control at each 
time point. Molecular masses are given in kilodaltons. Error bars indicate means ± SD. IB, immunoblot. IP, immunoprecipitation.JCB • VOLUME 193 • NUMBER 5 • 2011   872
Figure 4.  PKC mediates d-flow–induced p53 SUMOylation and p53–Bcl-2 binding. (A) HeLa cells were transfected for 24 h as indicated with Flag-
tagged p53, HA-tagged SUMO3, and HA-tagged CAT. p53 SUMOylation was detected by immunoprecipitation with anti-Flag followed by Western 
blotting with anti-SUMO2/3 (top). Both protein expression and immunoprecipitated p53 were confirmed by anti-Flag antibody, and CAT and SUMO 
expression were detected with anti-HA. Mono-SUMOylation band (74 kD) and poly-SUMOylation bands (>78 kD) were detected. The asterisk indicates 
mono-SUMOylation of p52. (B) HUVECs were transfected for 24 h with either PIASy or control siRNA as indicated, and then the cells were transfected 
with HA-CAT or vector alone for another 24 h. (top) p53 SUMOylation was detected by immunoprecipitation with anti-p53 followed by Western blotting 
with anti-SUMO2/3. PIASy expression was confirmed by immunoblotting with anti-PIASy, and p53, HA-CAT, and SUMO expression was confirmed with 
anti-p53, -HA, and -SUMO2/3, respectively. (C) HUVECs were transfected with either p53 or control siRNA as indicated for 24 h, and then the cells were 
transduced with an Ad-SENP2 or LacZ with a control for another 24 h. p53 SUMOylation, expression of p53, SENP2, and SUMO were determined as 
described in Materials and methods. The asterisks indicate nonspecific bands. (D) HUVECs were transduced with Ad-DN-PKC or Ad-LacZ as a control for 
24 h and then stimulated with d-flow for the indicated times. p53 SUMOylation and p53–Bcl-2 binding were determined as described in Materials and 
methods. (left graph) Intensities of SUMOylated p53 bands at 74, 82, 130, and 185 kD were quantified by densitometry after subtracting background 
gel density. After normalization of each control as described in Fig. 1, results were expressed relative to the SUMOylation level in static condition (0 min; 
100%). Shown are means ± SD (n = 3). **, P < 0.01 compared with the vehicle control or the LacZ control at each time point. (E) HUVECs were transfected 
with either PKC or control siRNA as indicated for 24 h and then stimulated with d-flow for 3 h. p53 SUMOylation, p53–Bcl-2 binding, expression of p53, 
Bcl-2, SUMO, and various PKC isoforms as indicated were determined as described in Materials and methods. Immunoblots are representative of three 
separate experiments. Molecular masses are given in kilodaltons. IB, immunoblot. IP, immunoprecipitation. KR, K386R. WT, wild type.873 D-flow–induced PKC activation and p53 SUMOylation • Heo et al.
p53 SUMOylation in HUVECs. When HUVECs were trans-
fected with PIASy siRNA, the ONOO
 and d-flow–dependent 
p53 SUMOylation was inhibited (Fig. 6 A and Fig. 7 A). Using 
the PIASy-depleted cells, we studied the role of PIASy in the 
ONOO
-elicited  p53–Bcl-2  association  and  found  that  the 
PIASy depletion inhibited this interaction (Fig. 6 B), suggesting 
that PIASy, which SUMOylates p53, is involved in ONOO
-
induced p53 nuclear export and subsequent p53–Bcl-2 binding 
in ECs. To see whether PIASy has a role in the ONOO
 and 
d-flow–induced EC apoptosis, ECs were transfected with PIASy 
siRNA, challenged by ONOO
 or d-flow, and assayed for apop-
tosis. The number of TUNEL-positive cells and expression of 
cleaved caspase 3 induced by ONOO
 or d-flow were down-
regulated by PIASy siRNA (Fig. 6 C and Fig. 7, B and C).
To establish the role of p53 SUMOylation on d-flow– 
mediated EC apoptosis, we transduced ECs with an adenovirus 
containing wild-type p53 (Ad-WT-p53) or the p53 SUMOylation 
site mutant (p53-K386R) and examined d-flow–mediated apop-
tosis compared with wild-type p53 in ECs. First, we confirmed 
that the adenoviral p53-K386R (Ad-p53-K386R) mutant signif-
icantly decreased p53 SUMOylation (Fig. 4 A). Next, we found 
that d-flow increased apoptosis in ECs transduced by Ad-WT-p53, 
but transduction of the Ad-p53-K386R mutant significantly in-
hibited it (Fig. 7, D and E). Because nuclear export of p53 is im-
portant for p53–Bcl-2 binding, we also used an NES mutation 
(L348,350A; NES; O’Keefe et al., 2003) and studied d-flow–
mediated EC apoptosis. As shown in Fig. S2 (A and B), in con-
trast to wild-type p53, we found that both p53-K386R and the 
NES mutant stayed in the nucleus after d-flow stimulation, 
and the NES mutant significantly inhibited d-flow–mediated 
apoptosis compared with wild type (Fig. 7, D and E), suggesting 
the critical role of p53 SUMOylation and nuclear export of 
p53 on d-flow–mediated EC apoptosis. Collectively, these results 
suggest the critical role of PIASy-mediated p53 SUMOylation 
and subsequent nuclear export of p53 in the ONOO
 and d-flow–
induced EC apoptosis (Fig. S2, A and B).
p53 SUMOylation is induced through 
PKC binding to PIASy instead of PIASy 
phosphorylation by PKC
As  PIASy  played  a  critical  role  in  CAT-mediated  p53   
SUMOylation (Fig. 4 B), PKC might directly phosphorylate 
PIASy and activate its E3 SUMO ligase activity. To test this 
possibility, we incubated recombinant PKC with GST-tagged 
PIASy fragments and found that none of the fragments was 
phosphorylated by PKC, whereas autophosphorylation of PKC 
was detected (Fig. S3). Although it does not phosphorylate PIASy, 
PKC may still interact with PIASy. We cotransfected HeLa 
cells with HA-tagged PKC and myc-tagged PIASy and per-
formed  a  coimmunoprecipitation  assay  in  which  PKC  and 
PIASy were coimmunoprecipitated (unpublished data). To con-
firm this interaction between endogenous PKC and PIASy, we 
stimulated HUVECs with ONOO
 for the indicated times and 
performed coimmunoprecipitation using anti-PKC. PIASy was 
indeed coimmunoprecipitated by anti-PKC, and ONOO
 stimu-
lation increased the PKC–PIASy interaction (Fig. 8 A). Next, to 
determine the PIASy-binding regions of PKC, we generated four 
proteins for conjugation as well as deconjugating SUMO from 
SUMOylated proteins (Cheng et al., 2004; Yeh, 2009; Witty   
et al., 2010). To verify the identity of the endogenous p53 
SUMOylation band, we also transduced ECs with Ad-LacZ con-
trol or adenoviral SENP2 (Ad-SENP2), stimulated them with 
d-flow, and evaluated changes in these multiple bands (Fig. 4 C). 
Transduction of Ad-SENP2 completely reduced d-flow–induced 
p53 SUMOylation. These results together support that the 68-, 74-, 
82-, 130-, 160-, 185-, and 200-kD bands are SUMOylated p53.
When HUVECs were treated with various concentrations 
of ONOO
 for 10 min, p53 SUMOylation increased in a dose-
dependent manner (Fig. S1, A and B). We also found that d-flow 
significantly increased p53 SUMOylation after 2 h of stimula-
tion (Fig. 4 D and Fig. S1 D). Next, we investigated whether 
PKC played a role in p53 SUMOylation by ONOO
 and   
d-flow. This SUMOylation was inhibited in cells expressing 
Ad-DN-PKC (Fig. 4 D and Fig. S1 C), suggesting a role of 
PKC in p53 SUMOylation in ONOO
 and d-flow–stimulated 
cells. In addition, Bcl-2 coimmunoprecipitated with p53 when 
control cells (transduced with Ad-LacZ) were treated with 
d-flow, but this coimmunoprecipitation was strongly inhibited 
by Ad-DN-PKC transduction (Fig. 4 D), which was also   
observed in ONOO
-treated cells (Fig. 3 D).
To  test  whether  PKC  plays  a  unique  role  on  p53   
SUMOylation and binding between p53 and Bcl-2, we transfected 
ECs with PKC siRNA and studied its effect on d-flow–mediated 
p53 SUMOylation and p53–Bcl-2 binding. As shown in Fig. 4 E, 
we found that PKC siRNA specifically inhibited PKC ex-
pression but not other PKC isoforms, including PKC/, PKC, 
PKCII, and PKC (Fig. 4 E). Under this condition, d-flow 
effects on p53 SUMOylation and p53–Bcl-2 binding were 
significantly reduced, indicating the unique and critical role 
of PKC on d-flow–mediated p53 SUMOylation and its sub-
sequent events.
ONOO
 production by d-flow mediates PKC 
activation and p53 SUMOylation
We investigated the contribution of ONOO
 production on 
the d-flow–mediated PKC activation and p53 SUMOylation 
and found that an ONOO
 scavenger, ebselen, a nonselective 
inhibitor of NO synthesis, N-nitro-l-arginine methyl ester 
(L-NAME), superoxide dismutase mimetic, and an ONOO
 
scavenger, Mn (III)tetrakis(4-benzoic acid)porphyrin chloride 
(Mn-TBAP), significantly inhibited d-flow–mediated PKC ac-
tivation as well as p53 SUMOylation (Fig. 5, A–C). Moreover, 
these compounds strongly inhibited d-flow–induced EC apop-
tosis (Fig. 5, D and E), strongly suggesting a critical role of 
ONOO
 production in the d-flow–mediated signaling and sub-
sequent apoptosis.
PIASy mediates p53 SUMOylation  
by ONOO
 and d-flow, and p53 
SUMOylation plays a critical role in  
d-flow–mediated apoptosis
Because  PIASy  (SUMO  E3  ligase)  is  involved  in  p53   
SUMOylation in fibroblasts (Bischof et al., 2006), we wondered 
whether it was involved in the ONOO
- and d-flow–elicited JCB • VOLUME 193 • NUMBER 5 • 2011   874
Figure 5.  ONOO
 mediates d-flow–induced PKC activation, p53 SUMOylation, and EC apoptosis. (A) ONOO
 mediates d-flow–induced PKC activa-
tion and p53 SUMOylation. HUVECs were pretreated by 5 µM ebselen, 20 µM L-NAME, and 10 µM Mn-TBAP for 30 min and exposed to d-flow for 3 h. 
PKC phosphorylation at Thr560 and p53 SUMOylation were determined as described in Materials and methods. (B and C) Densitometry analyses of 
p53 SUMOylation (B) and PKC phosphorylation (C) were performed as described in Fig. 1. **, P < 0.01 compared with the vehicle control in static 
condition, and 
#, P < 0.01 compared with the vehicle control in d-flow stimulation for 3 h. (D and E) HUVECs were pretreated by each inhibitor for 30 min 
and exposed to d-flow for 36 h followed by TUNEL staining as described in Materials and methods (D), and quantification of apoptosis is shown as the 
percentage of TUNEL-positive cells (E). Bars, 30 µm. Data are from three separate experiments using two or more different EC preparations (**, P < 0.01 
compared with the vehicle control in static condition, and 
#, P<0.05 and 
##, P<0.01 compared with the vehicle control in d-flow stimulation for 36 h). Error 
bars show means ± SD. Molecular masses are given in kilodaltons. IB, immunoblot. IP, immunoprecipitation.875 D-flow–induced PKC activation and p53 SUMOylation • Heo et al.
and PIASy together with PIASy Fr 3. Consistent with the co-
immunoprecipitation results, PIASy Fr 3 significantly inhibited 
the PKC–PIASy interaction (Fig. 8 E). To demonstrate the im-
portance of the PKC–PIASy interaction for p53 SUMOylation, 
ECs expressing PIASy fragments were stimulated by d-flow. As 
shown in Fig. 8 F, only PIASy Fr 3 inhibited d-flow–mediated p53 
SUMOylation,  suggesting  that  p53  SUMOylation  depends  on 
PKC–PIASy binding.
Morphological evidence for the PKC–PIASy and p53–
Bcl-2 association was provided by confocal microscopy of co-
immunostained ECs with or without flow stimulation (Fig. 9 A). 
Cells cultured without flow expressed PKC mainly in the cytosol 
and PIASy in the nucleus as reported previously (Sachdev et al., 
2001; Li et al., 2004). However, after d-flow stimulation, PKC 
and PIASy were colocalized in the nucleus. As for the p53 and 
Bcl-2 colocalization, p53 was localized in the nucleus of un-
stimulated cells, whereas Bcl-2 was mainly outside the nucleus 
PKC-truncated mutants and evaluated their association with 
PIASy using a mammalian two-hybrid assay (Fig. 8, B and C). 
Plasmids encoding the GAL4–DNA-binding domain and PKC 
(full length or one of the truncated forms) were constructed using 
the pBIND vector. A plasmid containing VP16-PIASy was con-
structed using the pACT vector. As expected, wild-type PKC 
bound to PIASy, and ONOO
 increased this association (Fig. 8 B). 
More importantly, however, we found that the C-terminal ki-
nase domain (aa 401–587) was required for the PKC–PIASy 
association (Fig. 8 C). Next, to determine the PKC binding 
site  of  PIASy,  we  coexpressed  GST-fused  PKC  and  Flag-
tagged PIASy fragments in HeLa cells and performed coimmuno-
precipitation using anti-Flag. We found that PIASy fragment 3 
(Fr 3; aa 301–410), which contains the Siz/PIAS RING domain, 
interacted with PKC (Fig. 8 D). In a separate experiment, we 
examined this fragment could interfere with the PKC–PIASy 
association. HeLa cells were cotransfected with wild-type PKC 
Figure 6.  ONOO
 induces p53 SUMOylation and p53–Bcl-2 binding via PIASy activation. (A and B) HUVECs were transfected with PIASy siRNA (si-PIASy) 
or control siRNA for 48 h and then stimulated with 100 µM ONOO
– for the indicated times. p53 SUMOylation (A) and p53–Bcl-2 binding (B) were deter-
mined as described in Materials and methods. (left) PIASy and p53 expressions were detected by Western blotting with appropriate specific antibodies. 
Densitometric analyses of p53 SUMOylation (A) and p53–Bcl-2 binding (B) were performed as described in Fig. 1. (C) HUVECs were transfected with 
PIASy or control siRNA for 48 h. After treatment with 100 µM ONOO
 for 8 h, apoptotic nuclei were detected by TUNEL staining. Data are expressed 
as mean percentages ± SD from three independent experiments. *, P < 0.05; **, P < 0.01. Molecular masses are given in kilodaltons. IB, immunoblot. 
IP, immunoprecipitation.JCB • VOLUME 193 • NUMBER 5 • 2011   876
Figure 7.  D-flow induces p53 SUMOylation and apoptosis via PIASy activation. (A) HUVECs were transfected with PIASy siRNA (si-PIASy) or control 
siRNA for 48 h and then stimulated with d-flow for the indicated times. p53 SUMOylation, expression of PIASy, p53, and SUMO2/3 were detected 
as described in Material and methods. Densitometric analyses of p53 SUMOylation were performed as described in Fig. 1. (B and C) HUVECs were 
transfected with PIASy or control siRNA for 48 h. After treatment with d-flow for 36 h, apoptotic nuclei were detected by TUNEL staining (B, bottom), 
and Western blotting with anti–cleaved caspase 3 (C, top) was performed. Immunoblots of PIASy conformed depletion of PIASy by the specific siRNA 
(B, top). Densitometry analysis of cleaved caspase 3 expression was performed as described in Fig. 2 C (bottom). The experiments were performed in 
triplicate using three different batches of d-flow–stimulated HUVECs. (D) HUVECs were transduced with an adenovirus vector containing p53, p53-K386R 
(KR; sumoylation defect mutant), or p53-NES (L348,350A; NES mutant) for 24 h and then stimulated with d-flow for 36 h followed by TUNEL staining 
as described in Materials and methods. (E, top) Quantification of apoptosis shown as the percentage of TUNEL-positive cells. Bars, 30 µm. (bottom) 
Equal expressions of p53, p53-K386R, and p53-NES were analyzed by Western blotting in ECs. Data are from three separate experiments using two 
or more different EC preparations. Error bars show means ± SD; *, P < 0.05; **, P < 0.01. Molecular masses are given in kilodaltons. IB, immunoblot. 
IP, immunoprecipitation. WT, wild type.877 D-flow–induced PKC activation and p53 SUMOylation • Heo et al.
Figure 8.  PKC–PIASy association is critical for p53 SUMOylation and p53–Bcl-2 binding. (A) HUVECs were stimulated with 100 µM ONOO
– for the indi-
cated times and subjected to immunoprecipitation with anti-PIASy followed by Western blotting with anti-PKC (top). (B and C) Association between PKC 
and PIASy was tested by a mammalian two-hybrid assay. HeLa cells were transfected with plasmids containing Gal4-PKC wild type and VP16-PIASy (B) 
or truncated mutants of VP16-PIASy (C) as well as the Gal4-responsive luciferase reporter pG5-luc. After 24 h of transfection, cells were stimulated with 100 µM   
ONOO
 or vehicle for 16 h, and luciferase activity was quantified. Luciferase activity was normalized with the Renilla luciferase (Luc.) activity (Woo et al., 
2008). Data are representative of three experiments using two or more different preparations of ECs (means ± SD; **, P < 0.01). (D) PIASy binding to 
PKC occurs via a domain consisting of aa 301–410 of PIASy. HeLa cells were transfected with each of the Flag-tagged PIASy fragments, and then pull-
down assays were preformed using anti-Flag and IgG Sepharose beads in the presence of GST-fused recombinant PKC. Association of PIASy fragments 
with GST-PKC was assayed by Western blotting with anti-PKC. (bottom) PIASy fragment expression was detected by Western blotting with anti-Flag.   
(E) PIASy Fr3, but not Fr4, inhibited PKC–PIASy association. HUVECs were cotransfected with HA-tagged PKC wild type, Myc-tagged PIASy wild type, 
and Flag-tagged PIASy Fr3 or Fr4 for 24 h. Myc-PIASy wild type was immunoprecipitated with anti-Myc followed by immunoblotting with anti-HA (top).   
The expression of PKC, PIASy, and PIASy fragments was detected by Western blotting with specific antibodies. Data are representative of three independent 
experiments. (F) HUVECs were transfected with Flag-tagged PIASy Fr3 or Fr4 or control vectors for 24 h and then stimulated by d-flow for 3 h. p53 was 
immunoprecipitated using anti-p53, and d-flow–induced p53 SUMOylation was analyzed by immunoblotting with anti-SUMO2/3 (top). The expression of 
p53, SUMO, and PIASy fragments was detected by Western blotting with specific antibodies. Data are representative of three independent experiments. 
Molecular masses are given in kilodaltons. IB, immunoblot. IP, immunoprecipitation. WT, wild type.JCB • VOLUME 193 • NUMBER 5 • 2011   878
atherogenesis (Fig. 10 A) as described previously (Iiyama et al., 
1999) and in the Materials and methods section. When the 
endothelium was double stained with anti-PKC or antiphospho-
PKC together with anti–vascular endothelial (VE)-cadherin as 
an EC marker, we found that the expression of total PKC in-
creased in the HP area (Fig. 10 B), and especially phospho-PKC 
was significantly higher in the HP area compared with the LP area 
(Fig. 10 C). Quantification of these data obtained from five mice 
supports this conclusion (Fig. 10, B and C, bar graph). These 
results confirm our in vitro results that show d-flow–dependent 
activation of PKC (Fig. 1).
Next, aortas were immunostained with anti-p53 and then 
with TO-PRO3 for nucleus staining, and confocal microscopy was 
used to acquire a z series of fluorescence images. No significant 
fluorescent signal was observed in aorta samples treated with 
nonimmune rabbit IgG (not depicted) or with antigen-preabsorbed 
anti-p53 (Fig. S5 A). In LP areas, p53 was localized mainly in 
the nucleus (Fig. 10, D and F). In contrast, in HP areas, significant 
levels of anti-p53 staining were detected outside the nucleus, 
as previously reported (Zhong et al., 1993; Ghosh et al., 2004). 
D-flow stimulation caused significant nuclear export of p53 and 
colocalization with Bcl-2. These data support d-flow–induced 
association of PKC–PIASy and p53–Bcl-2 in ECs.
En face immunohistochemistry of PKC, 
p53, nitrotyrosine, and apoptosis in 
mouse aorta
PKC activation in the ECs of the lesser curvature of the aortic 
arch in porcine aorta was recently reported (Magid and Davies, 
2005). Because activation of this kinase is proatherogenic, we 
investigated the expression of PKC, phosphorylated PKC, a 
nitrotyrosine-containing protein, p53, and apoptotic ECs using 
en face aorta preparations and confocal microscopy. Aortas from 
male wild-type C57BL/6 mice (6–8 wk old) fed with normal 
chow were isolated after perfusion fixation and en face prepara-
tions were made. We focused on areas designated as high prob-
ability (HP) regions (lesser curvature of aortic arch) and low 
probability (LP) regions (greater curvature of aortic arch) for 
Figure  9.  D-flow–induced  PKC–PIASy  asso-
ciation  in  nuclei  and  p53–Bcl-2  binding  in  the 
cytosol. (A and B) HUVECs were stimulated with 
either static or d-flow for 3 h and immunoassayed 
with antibodies of mouse anti-PKC and rabbit 
anti-PIASy  (A)  or  mouse  anti-p53  and  rabbit 
anti–Bcl-2 (B). After d-flow stimulation, yellow in 
the merged images represent colocalization be-
tween PKC and PIASy in nuclei or p53 and Bcl-2 
in cytosol. Images were recorded using a con-
focal microscope equipped with a Plapon 60× 
1.42 NA oil lens objective. Shown are represen-
tative images from cells analyzed from three in-
dependent experiments in which ≥30 cells were 
analyzed per experiment. Bars, 10 µm.879 D-flow–induced PKC activation and p53 SUMOylation • Heo et al.
apoptosis, especially under low stress conditions (Tian et al., 
2000; Garner and Raj, 2008). Indeed, our current study has re-
vealed the antiapoptotic localization of p53 in ECs in the LP 
area exposed to steady laminar stress, which we consider to be 
a low stress condition. In contrast, ECs exposed to d-flow and 
ONOO
  had  increased  cytoplasmic  p53  localization  (i.e., 
nuclear export of p53), which enhanced EC apoptosis via increased 
p53–Bcl-2 binding.
Little information is available regarding the pathological 
significance of p53 subcellular localization, especially in ECs. 
Our study suggests that PKC activation by d-flow and ONOO
 
and subsequent p53 nuclear export promote EC apoptosis. This 
notion is consistent with an earlier study showing that human 
cytomegalovirus infection of ECs induces p53 accumulation in 
the cytoplasm and apoptosis via a p53-dependent pathway (Shen 
et al., 2004). Together, these results strongly suggest the involve-
ment of cytoplasmic p53 in EC apoptosis (Utama et al., 2006). 
Our en face confocal data are consistent with this idea because 
increased cytoplasmic anti-p53 staining and increased TUNEL 
and annexin V stainings are found in ECs located in the area 
exposed to d-flow (i.e., HP area).
In our in vitro study, we found the importance of ONOO
 
on d-flow–mediated PKC activation, p53 SUMOylation, and 
EC apoptosis using ebselen, L-NAME, and Mn-TBAP (Fig. 5). 
In addition, we found that nitrotyrosine staining was significantly 
increased in d-flow (HP) areas in vivo (Fig. S5, B–D), where 
PKC activation, nuclear exports of p53, and EC apoptosis were 
increased. We used 10–100 µM ONOO
 as the final concentra-
tion, which is in agreement with the concentration of ONOO
 
used in previous studies by other investigators (Alvarez et al., 
2004; Levrand et al., 2005; Szabó et al., 2007). Because ONOO
 
is a transient intermediate in free radical chemistry and is highly 
reactive, it is difficult to measure actual concentrations of ONOO
 
in vivo. However, 10–100 µM ONOO
 are thought to be physi-
ological because it has been suggested that the rates of ONOO
 
production in vivo in specific compartments have been estimated 
to be as high as 50–100 µM/min (Alvarez et al., 2004; Levrand 
et al., 2005; Szabó et al., 2007). In addition, it has also been 
estimated that the rate of ONOO
 generation may reach up to   
1 mM/min in an inflamed organ (lung) in vivo (Ischiropoulos et al., 
1992). ONOO
 has several possible ways to activate PKC. 
One of the major effects of ONOO
 is protein tyrosine nitration, 
which can regulate a variety of kinases (Liaudet et al., 2009). First, 
ONOO
 can activate various receptor tyrosine kinases (Klotz 
et al., 2000; Zhang et al., 2000). Second, ONOO
 can activate 
Src by displacing Tyr527 from its binding site to the SH2 domain 
(Roskoski, 2005). Finally, ONOO
 can inhibit phosphatases via 
oxidation of cysteine-bound thiols (Takakura et al., 1999). 
Although the direct effect of ONOO
 on PKC remains unclear, 
these molecules may be involved in signaling events upstream of 
PKC. Therefore, we hypothesize that activation of a variety of ki-
nases may be involved in ONOO
-mediated PKC activation. Fur-
ther studies are necessary to determine the major signaling events.
In addition to regulating cell physiology through kinase ac-
tivities, active kinases can also regulate cell physiology by alter-
ing their interaction with other molecules (Akaike et al., 2004; 
Boggon and Eck, 2004). PKC contains the pseudosubstrate 
although anti-p53 staining was still associated with the nucleus. 
This cytoplasmic staining was localized primarily to the area 
underneath the nucleus (Fig. 10, E and F). These results appear to 
suggest that d-flow causes p53, which is present mainly in the 
nucleus in ECs exposed to s-flow (i.e., LP area), to translocate into 
the cytoplasm especially to the area directly below the nucleus.
We also examined whether ECs in the HP area underwent 
more apoptosis than ECs in the LP area. Aortas of 7-wk-old 
C57BL/6  mice  were  immunostained  first  for VE-cadherin 
(Fig. S4 A, red) followed by the TUNEL staining (Fig. S4 A) or 
were coimmunostained for annexin V (Fig. S4 B, red) and 
VE-cadherin (Fig. S4 B, green). Although, in the LP area, TUNEL- 
and annexin V–positive cells were rarely detected, such cells 
were frequently detected in the HP area (Fig. S4, A and B). 
Next, we studied the role of p53 in EC apoptosis in the 7-wk-old 
p53-deficient C57BL/6 mice (p53
/; Fig. 10, G and H). p53 
was absent in lung ECs isolated from p53
/ mice (Fig. 10 H, 
right). Interestingly, annexin V–positive cells in the HP area were 
significantly decreased in the p53
/ mice (Fig. 10, G and H), 
supporting the critical role of p53 on d-flow–mediated apoptosis   
in vivo. Because we found the critical role of ONOO
 in d-flow–
mediated PKC activation, p53 SUMOylation, and apoptosis, 
we investigated the expression of nitrotyrosine-containing proteins 
by double staining aortas with anti–VE-cadherin and antinitrotyro-
sine (Fig. S5, B–D). Antinitrotyrosine staining was significantly 
higher in HP areas than in LP areas. Our data collectively suggest 
that d-flow induces ONOO
 production, PKC activation, and nu-
clear export of p53, which increases EC apoptosis, and may prime 
ECs in the d-flow (HP) area to become susceptible to atherogenesis 
under the influence of various systemic risk factors.
Discussion
Several atheroprotective signals activated by s-flow have been 
identified, but atheroprone signaling activated by d-flow is not 
well understood. The main finding of this study is that d-flow–
mediated ONOO
 production activates PKC and induces p53 
SUMOylation, p53 nuclear export, p53–Bcl-2 binding, and sub-
sequent apoptosis. p53 appears to have both yin and yang effects 
on blood vessel physiology. Recent studies show its protective 
effect against cell death (Tian et al., 2000; Garner and Raj, 2008). 
Because p53 positively regulates the expression of p21, an anti-
apoptotic protein (Garner and Raj, 2008), p53 may exert its anti-
apoptotic effect by increasing p21 expression. Previously, Lin 
et al. (2000) have reported that laminar shear stress increased 
p53 expression and JNK-mediated p53 phosphorylation, which 
leads to endothelial growth arrest via increasing GADD45 and 
p21
cip1 expression. Therefore, it is important to emphasize here 
that p53 can induce growth arrest by inhibiting apoptosis via 
regulating p21. The interplay between cell cycle arrest and apop-
tosis is possibly critical in maintaining endothelial function be-
cause p53 may be able to reduce cells with DNA damages from 
apoptosis by preventing entry into the S phase (Garner and Raj, 
2008). However, it remains unclear how p53 determines which 
of these two activities, pro- or antiapoptotic, to implement. Of 
note, most of the p53 antiapoptotic effects have been explained 
by its nuclear localization, as nuclear p53 protects cells from JCB • VOLUME 193 • NUMBER 5 • 2011   880
Figure 10.  Increases in phosphorylated and total PKC and nonnuclear p53 expression within the d-flow regions (HP areas) and decreased apoptosis 
in ECs of p53
/ mice. (A) A representative epifluorescence image of the whole specimen. Fixed aortas of wild-type mice were cut longitudinally, and the 
arch region was further cut into two halves. Areas of d-flow (HP area; lesser curvature) are outlined in red, and neighboring areas of s-flow (LP area) are 
lined in blue. a, artery. (B and C) En face preparations were double stained with anti–VE-cadherin (VE-cad; used as an EC marker) and an anti–total PKC 
antibody (B) or phospho-PKC T560 antibody (C). X-y axis images were collected at 0.5-µm increments so that a z stack of 4-µm thickness from the luminal 
surface was obtained. From each image background, fluorescence intensity was subtracted, and the pixel number of the stained region per unit area of the 
endothelium in HP and LP area within the aortic arch was determined (n = 3). Areas of d-flow (HP areas; lesser curvature) show both increased total and 
phospho-PKC expression compared with the neighboring areas of s-flow (LP area). Bars, 20 µm. Bar graphs show quantification of total (B) and phospho 
(C)-PKC in HP and LP areas. Data are shown as means ± SEM; *, P < 0.05. (D and E) Increased cytoplasmic p53 localization in HP area ECs. Aortic 
arches were immunostained for endothelial p53 (green). Nuclei were stained using TO-PRO3 (red). From initial stacked x-y axis images (top), a narrow 
rectangular area crossing an EC was selected for x-y-z scanning at 0.1-µm increments. Images below the clipped images show rectangular z-axis images. 
Two representative sets of images (i and ii) are shown for LP (D) and HP (E) areas. Bars, 10 µm. (F) Quantification of nuclear p53. The pixel number of 881 D-flow–induced PKC activation and p53 SUMOylation • Heo et al.
antibodies for p-PKC were purchased from Cell Signaling Technology (Thr 
410; 9378) and Abcam (Thr 560; ab62372). The rabbit and mouse anti-
SUMO2/3 were purchased from Abgent (AP1224a) and MBL Interna-
tional  (M114-3),  respectively.  Anti-PIASy  was  purchased  from  Abcam 
(ab58416)  and  Sigma-Aldrich  (P0104).  Rat  anti–VE-cadherin  was  pur-
chased from BD (555289). ON-TARGETplus SMARTpool for human PKC 
siRNA was purchased from Thermo Fisher Scientific (L-003526-00), and a 
nonspecific control siRNA obtained from Invitrogen (12935-122) was used 
as a negative control. The Ad-DN-PKC was purchased from Cell Biolabs. 
The Ad-DN-PKC was generated by mutating the ATP binding site (K281M) 
from human PKC (NCBI Protein database accession no. NP_002735; 
Diaz-Meco et al., 1993). GST-fused active recombinant human PKC was 
purchased from Stressgen (PPK-468). Peroxynitrite was purchased form 
EMD. Alexa Fluor 488–conjugated mouse antinitrotyrosine was purchased 
from Millipore (16–226).
Cell culture and transfection of the PKC and PIASy siRNAs
HUVECs were obtained from collagenase-digested umbilical cord veins 
(Takahashi and Berk, 1996) and collected in M200 medium supplemented 
with low serum growth supplement (Cascade Biological) and 5% fetal calf   
serum (Invitrogen). HUVECs were cultured on 0.2% gelatin-precoated dishes. 
For transient expression experiments, transfection of the PKC SMARTpool 
siRNA or PIASy siRNA was performed using Lipofectamine 2000 (Invitro-
gen) following protocols provided by the manufacturer. The Stealth RNAi 
Negative Control Med GC (Invitrogen), which has no homology to the 
vertebrate transcriptome, was used as a negative control. The cells were   
harvested 48 h after siRNA transfection, and protein expressions were mon-
itored by immunoblotting with antibodies against PKC, PIASy, or tubulin.   
The target and control sequences for PIASy siRNAs were 5-CAAGACAG-
GUGGAGUUGAU-3 and 5-UACCGUCUCCACUUGAUCG-3.
Flow apparatus
To expose a large number of cells to flow, we used a cone and plate flow 
apparatus identical to the one used previously (Reinhart-King et al., 2008). 
Confluent HUVECs cultured in 100-mm dishes were exposed to s-flow in a 
flow apparatus placed in a cell culture incubator with 5% CO2 and at 
37°C for long-term experiments (shear stress = 20 dyn/cm
2). To expose 
cells to d-flow, we used a cone with radial grooves. Shear stress induced 
by d-flow cannot be calculated, but we rotated the cone with 50 rpm that 
gives 5 dyn/cm
2 of laminar shear stress. We optimized and chose this 
speed because ECs maintained nonelongated cell shapes with this speed.
Analysis of apoptosis
In accordance with recently published guidelines, apoptosis was quanti-
fied by multiple methodologically unrelated criteria (Galluzzi et al., 2009). 
To induce apoptosis, HUVECs were treated with 100 µM ONOO
 or d-flow. 
Phosphatidylserine externalization was quantified by staining cells with 
annexin V–Alexa Fluor 568 (Roche), and late-stage apoptosis was quantified 
morphologically by counting cells showing evidence of positive staining for 
TUNEL (Ding et al., 2000). TUNEL analyses were performed according to 
the manufacturer’s instructions, and the cells were counterstained with DAPI 
(Sigma-Aldrich) to identify nuclei. For each experiment in vitro, a total of 
150–200 cells were counted from randomly selected fields of view, and 
TUNEL-positive cells were expressed as a percentage of total cells counted. 
Samples were examined using a 40× lens under a fluorescence micro-
scope (BX51; Olympus) capable of imaging two distinct channels without 
adjustment of the microscope stage position. 10 random fields per sample 
were examined. Apoptosis was also quantified by Western blot assessment 
of the cleavage of the caspase 3 using the cleaved caspase 3 antibody. All 
measurements were performed blinded, and at least three independent 
experiments were performed.
Mammalian two-hybrid analysis and transfection of cells
Cells were plated in 12-well plates at 5 × 10
4 cells/well. The mammalian two-
hybrid assay was performed as described previously (Woo et al., 2006). 
autoinhibitory sequence (aa 116–122), and the release of the 
kinase domain (aa 268–587) from this autoinhibitory domain 
leads to PKC activation (Newton, 2001; Smith et al., 2003). In this 
study, we were unable to show PKC-mediated phosphorylation 
of PIASy in our in vitro kinase assay (Fig. S3), but we found 
that activation of PKC increased the PKC–PIASy interaction 
(Fig. 8). Using a mammalian two-hybrid assay, we then deter-
mined the C-terminal kinase domain of PKC (aa 401–587) was 
a PIASy binding site (Fig. 8 C). Of note, the deletion of the 
N-terminal autoinhibitory domain of PKC (aa 1–200) increased 
PKC–PIASy association, suggesting that this domain is a neg-
ative regulator not only of its kinase activity but also its binding 
ability with PIASy. Therefore, releasing the PKC N-terminal 
inhibitory effect (i.e., activation of PKC) is critical for both kinase 
activation and PKC–PIASy association, and the regulation of 
PIASy activity most likely depends on PKC-mediated increase 
in PKC–PIASy association but not phosphorylation. We also 
found that PKC binds to the RING domain of PIASy, which 
contains its catalytic site and may alter the structure and enzymatic 
activity of PIASy. Our findings suggest that d-flow–mediated 
PKC–PIASy association is critical for p53 SUMOylation to 
induce the endothelial p53 nuclear export and apoptosis.
Materials and methods
Animals
C57BL/6 and p53
/ mice with a C57BL/6 background (P53N4-M) were 
purchased from Taconic. All mice were maintained under pathogen-free 
conditions at the Aab Cardiovascular Research Institute at the University of 
Rochester. All animal procedures were performed with the approval of the 
University Committee on Animal Resources at the University of Rochester.
Plasmid and adenovirus vector construction
The plasmid encoding human HA-SUMO3 was a gift from R.T. Hay (Uni-
versity of Manchester, Manchester, England, UK; Tatham et al., 2001). The 
pcDNA3-Myc-PIASy  and  pcDNA-HA-PKC  constructs  were  gifts  from   
M. Takahashi (Nagoya University, Chikusa-ku, Nagoya, Japan; Matsuura 
et al., 2005) and J.-W. Soh (Columbia University, New York, NY; Soh et al., 
1999), respectively. The p53-luciferase (p53-luc) reporter (Addgene plas-
mid 16442; B. Vogelstein, Johns Hopkins University School of Medicine, 
Baltimore, MD; el-Deiry et al., 1993) and pcDNA-Flag-p53 (Addgene plas-
mid 10838; T. Roberts, Harvard Medical School, Boston, MA; el-Deiry 
et al., 1993; Gjoerup et al., 2001) were obtained from the nonprofit Add-
gene plasmid repository. The Gal4 wild-type and truncated forms of PKC 
were created by inserting a KpnI–XbaI fragment generated by PCR into the 
pBIND vector (Promega). V16-PIASy was created by inserting human PIASy 
isolated from pcDNA3-PIASy into BamH1 and EcoRV1 sites of the pACT vec-
tor. Truncated forms of PIASy were constructed by inserting fragments EcoRI–
XhoI or BamHI–XhoI generated by PCR into the pGEX-KG or pCMV-Taq2B 
vector, respectively. All constructs were verified by DNA sequencing.
Antibodies, siRNA, adenovirus, and reagents
Rabbit and mouse anti-PKC (C-20 [SC-216] and A-3 [SC-17781]), rabbit 
and mouse anti-p53 (FL-393 [SC-6243] and DO-1 [SC-126]), rabbit and 
mouse anti–Bcl-2 (N-19 [SC-492] and C-2 [SC-7382]), rabbit and mouse 
anti-HA (Y-11 [SC-805] and F-7 [SC-7392]), and anti-myc (A-14; SC-789) 
were purchased from Santa Cruz Biotechnology, Inc. The phospho-specific 
nuclear and nonnuclear regions per cell was determined, and the ratio of nuclear/total intensity was calculated from 60 cells from each HP and LP area 
(four cells/field, five fields/mouse, and a total of three mice). (G) The number of d-flow–mediated annexin V–positive cells (red) in the HP area is decreased 
in the mice deficient for p53 (p53 knockout) compared with the wild-type mouse aorta. Anti–VE-cadherin staining (green) was used as a marker for ECs. 
Bars, 100 µm. (H, left) Quantification of apoptotic cells. Percentages of annexin V–positive cells in LP and HP areas determined from 7-wk wild-type and 
p53-deficient mice (n = 3 each) are shown. In HP area, the number of annexin V–positive cells are significantly decreased in the p53 knockout compared 
with the wild type. **, P < 0.01. (right) Deletion of p53 was confirmed by Western blotting with anti-p53 using a lung protein lysate. Molecular masses 
are given in kilodaltons. Data are shown as means ± SEM. WT, wild type.
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En face immunohistochemistry
The s-flow and d-flow areas within the aorta were identified based on the 
published and generally accepted anatomical locations where such flow 
patterns are known to occur (Iiyama et al., 1999; Hajra et al., 2000; 
Jongstra-Bilen et al., 2006). For example, a typical s-flow area is located 
in the greater curvature area and is marked as an LP region for lesion for-
mation (Hajra et al., 2000), which is also known as a high wall shear stress 
area. A d-flow area is the lesser curvature area (HP region; Iiyama et al., 
1999; Hajra et al., 2000; Jongstra-Bilen et al., 2006), which is also indi-
cated as a low wall shear stress area. In the Fig. 10 legend, we indicated 
these two areas in the aortic arch. EC shape outlined by anti–VE-cadherin 
staining was also used to identify s-flow areas (elongated cell shape) and 
d-flow areas (irregular cell shape). It has been reported that PECAM-1 
(CD31) staining, another marker of ECs, was localized to endothelial junc-
tions in the HP region, whereas in the LP region, it is more diffuse. There-
fore, the PECAM-1 staining at EC borders was much stronger in the HP 
region than in the LP region (Hajra et al., 2000). We found the similar ten-
dency of VE-cadherin staining in the mouse aorta. Because these data 
were very consistent in every mouse, we do not think that this is caused by 
the damage that specifically occurred in the LP region. C57BL/6 wild-type 
mice (Taconic) were fed standard chow. Animals of 6–8 wk of age were 
euthanized by CO2 inhalation. The arterial tree was perfused via the left 
ventricle with saline containing 40 USPU/ml heparin followed by 4% para-
formaldehyde in PBS for 10 min. After adipose tissues were removed, aor-
tas were cut open longitudinally and permeabilized with PBS containing 
0.1% Triton X-100 and blocked by TBS containing 10% goat serum and 
2.5% Tween 20 for 30 min. Aortas were incubated with 10 µg/ml rabbit 
anti-p53 (FL-393; Santa Cruz Biotechnology, Inc.; rabbit IgG was used as 
a control) and 7 µg/ml rat anti–VE-cadherin (an EC marker; BD) in the 
blocking solution overnight. Specificity of anti-p53 staining was tested by 
staining with anti-p53 preabsorbed with recombinant p53 (Santa Cruz 
Biotechnology, Inc.) as shown in Fig. S4. After a PBS rinse, anti–rabbit IgG 
and anti–rat IgG (1:1,000 dilution; Alexa Fluor 546 and 488, respec-
tively; Invitrogen) were applied for 1 h at room temperature. Nuclei were 
stained using TO-PRO3 (Invitrogen). For the detection of apoptosis, we 
used two different methods. To perform an in situ TUNEL assay, aortas im-
munostained with anti–VE-cadherin (with Alexa Fluor 546 anti–rabbit IgG) 
were incubated in the TUNEL reaction mixture (Roche) for 1 h at 37°C ac-
cording to the manufacturer’s instructions (mixture without the enzyme TdT 
as a control). For annexin V labeling, we injected annexin V–Alexa Fluor 
568 into aortas via the left ventricle after perfusion with saline containing 
40 USPU/ml heparin followed by 4% paraformaldehyde in PBS for 10 min. 
Then, these aortas were immunostained with anti–VE-cadherin as described 
in the previous paragraph. Images were acquired using a confocal laser-
scanning microscope (Fluoview 300; Olympus) equipped with krypton/
argon/HeNe laser lines and 20× 0.70 NA, 40× 1.0 NA, and 60× 1.4 NA 
objectives. For quantification of phospho- and total PKC expression level, 
10–15 optical sections were collected at 0.3–0.5-µm increments so that   
z stacks of 4-µm-thick cell blocks from the luminal surface were obtained. 
Images were collected using the same confocal settings. For quantification 
of EC apoptosis, aortas of 7-wk-old wild-type mice (n = 7 each) were pre-
pared. Images were acquired as described in the previous paragraph. 
To analyze p53 subcellular localization, we took z-stack clip images of 
50 optical sections collected at 0.1-µm increments from the luminal sur-
face. We radially extended the edge of the nucleus by the length of the 
nuclear radius at each point along the edge of the nucleus and delineated 
an area for each cell. We defined the signal level in this area as total be-
cause practically all anti-p53 staining signals (>80–90%) were included in 
this area. Staining signal levels in the cytoplasm and the nucleus were de-
termined. Confocal images were obtained from s-flow and d-flow areas as 
shown in Fig. 10.
Statistical analysis
Data are reported as means ± SD. Statistical analysis was performed with 
the Prism program version 2.00 (GraphPad Software). Differences were 
analyzed with a one-way or a two-way repeated-measure analysis of vari-
ance as appropriate followed by Dunnett’s correction for multiple compari-
sons. P < 0.05 is indicated by an asterisk, and P < 0.01 is indicated by a 
double asterisk.
Online supplemental material
Fig. S1 shows that ONOO
 increases p53 SUMOylation and p53–Bcl-2 
binding. Fig. S2 shows d-flow–induced p53 nuclear export analyzed by 
immunostaining. Fig. S3 shows whether PKC phosphorylates PIASy in vitro 
by in vitro kinase assay. Fig. S4 shows apoptosis in d-flow and s-flow area of   
the mouse aortic arch endothelia analyzed by TUNEL and annexin V staining. 
In brief, cells were transfected in Opti-MEM (Invitrogen) with Lipofectamine 
mixture containing the pG5-luc vector and various pBIND and pACT plas-
mids (Promega) for 4 h. Cells were washed, and fresh DME supplemented 
with 10% fetal bovine serum was added. The pBIND vector contains the 
yeast GAL4–DNA-binding domain upstream of a multiple cloning region, 
and the pACT vector contains the herpes simplex virus VP16 activation do-
main upstream of a multiple cloning region. Various PKC mutants and 
PIASy were cloned into the pBIND and pACT vector, respectively. Because 
pBIND also contains the Renilla luciferase gene, the expression and trans-
fection  efficiencies  were  normalized  with  the  Renilla  luciferase  activity. 
Cells were collected 36 h after transfection unless indicated otherwise, and 
the luciferase activity was assayed with the Dual-Luciferase kit (Promega) 
using a luminometer (TD-20/20; Turner Designs). Transfections were 
performed  in  triplicate,  and  each  experiment  was  repeated  at  least 
three times.
GST pull-down assay
HeLa cells (10
6 cells) were plated in 100-mm dishes and transfected in 
Opti-MEM with Lipofectamine mixture containing the Flag-tagged PIASy-
truncated mutants for 4 h. Cells were washed and cultured for 24 h in fresh 
complete growth medium. Cell lysates were made by incubating cells in 
0.5 ml radioimmunoprecipitation assay lysis buffer for 30 min at 4°C. After 
centrifugation for 20 min at 12,000 rpm, the whole-cell lysates were incu-
bated with 100 ng of recombinant GST-fused PKC, anti-FLAG, and IgG 
Sepharose beads with constant mixing for 2–5 h at 4°C. The beads were 
then washed three times with lysis buffer, resuspended in SDS-PAGE sam-
ple buffer, and boiled for 8 min. Samples were separated on a 15% SDS-
PAGE and analyzed by Western blotting using anti-PKC.
Immunohistochemistry and confocal microscopy
To determine whether the p53 localization is regulated by PKC activation, 
HUVECs grown in 6-well plates were transduced with Ad-LacZ or Ad-
DN-PKC for 24 h. After treatment with 100 µM ONOO
 for 4 h, the cells 
were quickly washed two times with cold PBS, fixed with 4% paraformal-
dehyde in PBS for 15 min, and then permeabilized with 0.2% Triton X-100 
in PBS for 10 min. Cells were incubated with blocking buffer (5% goat 
serum and 0.1% NP-40 in PBS) for 60 min to block nonspecific binding and 
incubated with anti-p53 (1:200 dilution in 2% goat serum and 0.1% NP-40 
in PBS) overnight at 4°C. The cells were washed three times with PBS and 
incubated with Alexa Fluor 546–labeled anti–rabbit IgG or Alexa Fluor 
488–labeled  anti–rabbit  IgG1  (1:2,000  dilution;  Invitrogen)  for  1  h  at 
room temperature. The cells were counterstained with DAPI to identify 
nuclei. All of the images were collected using an epifluorescence microscope 
(BX51) equipped with a charge-coupled device camera (Spot; Diagnostic 
Instruments, Inc.) and an Acroplan water 60× W lens.
To  determine  the  colocalization  of  p53  with  Bcl-2  or  PKC  with 
PIASy, HUVECs were stimulated with d-flow for 3 h. After fixation, perme-
abilization, and 10% goat serum in PBS with 0.1% NP-40 for 1 h, the cells 
were incubated with mouse anti-p53 and rabbit anti–Bcl-2 or mouse anti-
PKC and rabbit anti-PIASy (1:200) antibodies in 2% goat serum with PBS 
overnight at 4°C. The cells were washed three times with PBS and incu-
bated  with  Alexa  Fluor  546–labeled  anti–mouse  IgG  and  Alexa  Fluor 
488–labeled anti–rabbit IgG1 (1:2,000 dilution) for 1 h at room temperature. 
The samples were analyzed using a laser-scanning confocal microscope 
(FV1000; Olympus) equipped with a Plapon 60× 1.42 NA oil lens objec-
tive. Quantification of the overlay image was performed using the Photo-
shop (CS; Adobe) program.
Immunoprecipitation (SUMO assay) and Western blot analysis
Cells were collected in PBS containing 10 mM N-ethylmaleimide, and cell 
extracts were prepared in modified radioimmunoprecipitation assay buffer 
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% 
SDS, 1 mM dithiothreitol, 1:200-diluted protease inhibitor cocktail [Sigma-
Aldrich], 1 mM PMSF, 10 mM N-ethylmaleimide, and 0.1 mM iodoacet-
amide). Immunoprecipitation with a mouse monoclonal anti-Flag, HA, or 
p53 was performed as described previously (Woo et al., 2006). Bound 
proteins were released in 2× SDS sample buffer, resolved by SDS-PAGE, 
transferred onto an enhanced chemiluminescence nitrocellulose membrane 
(Hybond), and visualized by using the enhanced chemiluminescence de-
tection reagents (GE Healthcare) according to the manufacturer’s instruc-
tions.  p53  SUMOylation  was  detected  by  immunoprecipitation  with 
anti-p53 followed by Western blotting with anti-SUMO2/3. Results were 
normalized to the lowest phosphorylation level within each set of experi-
ments, and statistical significance was determined by comparing the mean 
level of the control group to each of the experimental data points.883 D-flow–induced PKC activation and p53 SUMOylation • Heo et al.
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